|
EP1392359B2
(en)
|
2001-05-11 |
2013-03-13 |
Ludwig Institute for Cancer Research Ltd. |
Specific binding proteins and uses thereof
|
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
|
US7498298B2
(en)
|
2003-11-06 |
2009-03-03 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation to ligands
|
|
NZ565075A
(en)
*
|
2005-06-20 |
2011-05-27 |
Psma Dev Company Llc |
PSMA antibody-drug conjugates
|
|
USRE47223E1
(en)
|
2005-06-20 |
2019-02-05 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
US7750116B1
(en)
*
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
|
US9090693B2
(en)
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
|
ES2542152T3
(es)
|
2007-03-15 |
2015-07-31 |
Ludwig Institute For Cancer Research Ltd. |
Método de tratamiento que emplea anticuerpos de EGFR e inhibidores de Src y formulaciones relacionadas
|
|
EP2144628B1
(en)
*
|
2007-05-08 |
2012-10-17 |
Genentech, Inc. |
Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
|
|
DK2474557T3
(da)
|
2007-07-16 |
2014-11-10 |
Genentech Inc |
Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
|
|
NZ583318A
(en)
|
2007-07-16 |
2012-07-27 |
Genentech Inc |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
|
CN108424454B
(zh)
|
2007-08-14 |
2022-05-31 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
|
RU2476441C2
(ru)
|
2007-10-19 |
2013-02-27 |
Сиэтл Дженетикс, Инк. |
Cd19-связывающие средства и их применение
|
|
SG187517A1
(en)
|
2008-01-31 |
2013-02-28 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
EP2326350B1
(en)
|
2008-09-08 |
2013-09-04 |
Psma Development Company, L.L.C. |
Compounds for killing psma-expressing, taxane-resistant cancer cells
|
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
MY173390A
(en)
|
2009-10-23 |
2020-01-22 |
Takeda Pharmaceuticals Co |
Anti-gcc antibody molecules and related compositions and methods
|
|
CN103200950B
(zh)
|
2010-06-10 |
2016-03-16 |
西雅图基因公司 |
新颖的耳他汀衍生物及其用途
|
|
US8987209B2
(en)
|
2010-09-29 |
2015-03-24 |
Seattle Genetics, Inc. |
N-carboxyalkyl-auristatin and the use thereof
|
|
US9540443B2
(en)
|
2011-01-26 |
2017-01-10 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies
|
|
US9029406B2
(en)
|
2011-03-16 |
2015-05-12 |
Seattle Genetics, Inc |
N-carboxyalkylauristatins and use thereof
|
|
KR102023496B1
(ko)
|
2011-04-21 |
2019-09-20 |
시애틀 지네틱스, 인크. |
신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
|
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
|
US20130190248A1
(en)
*
|
2011-07-26 |
2013-07-25 |
Agensys, Inc. |
Substituted peptide analogs
|
|
MY168297A
(en)
|
2011-11-17 |
2018-10-23 |
Pfizer |
Cytotoxic Peptides and Antibody Drug Conjugates Thereof
|
|
EP3575794A1
(en)
|
2012-02-10 |
2019-12-04 |
Seattle Genetics, Inc. |
Detection and treatment of cd30+ cancers
|
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
|
CN116574185A
(zh)
|
2012-07-25 |
2023-08-11 |
塞尔德克斯医疗公司 |
抗kit抗体及其用途
|
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
|
JP6262768B2
(ja)
*
|
2013-01-03 |
2018-01-17 |
セルトリオン， インク． |
抗体−リンカー−薬物結合体、その製造方法およびそれを含む抗癌剤組成物
|
|
PL2968440T3
(pl)
|
2013-03-15 |
2019-12-31 |
Zymeworks Inc. |
Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania
|
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
|
WO2015057876A1
(en)
*
|
2013-10-15 |
2015-04-23 |
Sorrento Therapeutics Inc. |
Drug-conjugates with a targeting molecule and two different drugs
|
|
ES2826398T3
(es)
|
2013-10-15 |
2021-05-18 |
Seagen Inc |
Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco
|
|
BR112016012538A2
(pt)
|
2013-12-17 |
2017-09-26 |
Novartis Ag |
peptídeos citotóxicos e conjugados dos mesmos
|
|
AU2014373640B2
(en)
|
2013-12-27 |
2018-08-30 |
Var2 Pharmaceuticals Aps |
VAR2CSA-drug conjugates
|
|
RU2729194C2
(ru)
|
2013-12-27 |
2020-08-05 |
Займворкс Инк. |
Сульфонамидсодержащие связывающие системы для лекарственных конъюгатов
|
|
EP3149024B9
(en)
*
|
2014-05-28 |
2021-10-27 |
Agensys, Inc. |
Cytotoxic dolaproine-dolaisoleuine peptide derivatives for the treatment of cancer
|
|
CN106573956A
(zh)
*
|
2014-06-13 |
2017-04-19 |
诺华股份有限公司 |
澳瑞他汀衍生物及其缀合物
|
|
AU2015318556C1
(en)
|
2014-09-17 |
2021-01-07 |
Zymeworks Bc Inc. |
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
|
PT3262071T
(pt)
|
2014-09-23 |
2020-06-16 |
H Hoffnabb La Roche Ag |
Métodos de utilização de imunoconjugados anti-cd79b
|
|
JP6864953B2
(ja)
|
2014-12-09 |
2021-04-28 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Ａｘｌに対するヒトモノクローナル抗体
|
|
CN106279352B
(zh)
|
2015-05-29 |
2020-05-22 |
上海新理念生物医药科技有限公司 |
海兔毒素10的衍生物及其应用
|
|
WO2017060397A1
(en)
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from melanoma metastases
|
|
EP3362178B1
(en)
|
2015-10-12 |
2024-01-24 |
Labcyte Inc. |
Systems and methods for tagging and acoustically characterizing containers
|
|
WO2017067944A1
(en)
|
2015-10-19 |
2017-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from triple negative breast cancer
|
|
JP6486316B2
(ja)
|
2015-11-03 |
2019-03-20 |
財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ |
抗体−薬物複合体（ａｄｃ）およびそれを形成するための方法
|
|
EP4509180A3
(en)
|
2016-03-22 |
2025-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Humanized anti-claudin-1 antibodies and uses thereof
|
|
KR20180134351A
(ko)
|
2016-03-25 |
2018-12-18 |
시애틀 지네틱스, 인크. |
페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
|
|
JP2019513371A
(ja)
|
2016-04-01 |
2019-05-30 |
アビディティー バイオサイエンシーズ エルエルシー |
核酸ポリペプチド組成物とその使用
|
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
|
US10517958B2
(en)
|
2016-10-04 |
2019-12-31 |
Zymeworks Inc. |
Compositions and methods for the treatment of platinum-drug resistant cancer
|
|
BR112019008345A8
(pt)
|
2016-10-25 |
2023-03-07 |
Inst Nat Sante Rech Med |
Anticorpos monoclonais ligados à isoforma transmembrana cd160
|
|
US10864279B2
(en)
|
2016-12-16 |
2020-12-15 |
Industrial Technology Research Institute |
Linker-drug and antibody-drug conjugate (ADC) employing the same
|
|
EP3554544A4
(en)
|
2016-12-16 |
2020-07-29 |
Bluefin Biomedicine, Inc. |
ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
|
|
MX2019008199A
(es)
|
2017-01-06 |
2019-11-25 |
Avidity Biosciences Llc |
Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
|
|
JP7341060B2
(ja)
|
2017-02-10 |
2023-09-08 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
|
|
AU2018237683A1
(en)
|
2017-03-24 |
2019-10-31 |
Seagen Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
|
WO2018209239A1
(en)
|
2017-05-11 |
2018-11-15 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
|
US20210403573A1
(en)
|
2017-06-22 |
2021-12-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells
|
|
MX2019015057A
(es)
|
2017-06-23 |
2020-08-03 |
Velosbio Inc |
Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1).
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
AU2018308088B2
(en)
|
2017-07-25 |
2025-05-29 |
Truebinding, Inc. |
Treating cancer by blocking the interaction of TIM-3 and its ligand
|
|
WO2019071028A1
(en)
|
2017-10-04 |
2019-04-11 |
Avidity Biosciences Llc |
NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
JP7506601B2
(ja)
|
2017-12-06 |
2024-06-26 |
アビディティー バイオサイエンシーズ，インク． |
筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法
|
|
EP3498293A1
(en)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Treatment of monogenic diseases with an anti-cd45rc antibody
|
|
WO2019217457A1
(en)
|
2018-05-07 |
2019-11-14 |
Genmab A/S |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
|
WO2019217455A1
(en)
|
2018-05-07 |
2019-11-14 |
Genmab A/S |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
|
TWI851577B
(zh)
|
2018-06-07 |
2024-08-11 |
美商思進公司 |
喜樹鹼結合物
|
|
EP3853251A1
(en)
|
2018-09-19 |
2021-07-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
|
EP3626265A1
(en)
|
2018-09-21 |
2020-03-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-human cd45rc antibodies and uses thereof
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
|
|
JP2022512860A
(ja)
|
2018-11-06 |
2022-02-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
白血病幹細胞を根絶することによる急性骨髄性白血病の治療のための方法および医薬組成物
|
|
US12583932B2
(en)
|
2018-11-16 |
2026-03-24 |
Virtuoso Binco, Inc. |
CD38 and ICAM1 antibodies and uses thereof
|
|
EP3894543A1
(en)
|
2018-12-14 |
2021-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8cd45rc low tregs
|
|
IL312067B2
(en)
|
2018-12-21 |
2025-08-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and uses thereof
|
|
AU2020214796A1
(en)
|
2019-01-30 |
2021-07-29 |
Truebinding, Inc. |
Anti-Gal3 antibodies and uses thereof
|
|
US12497615B2
(en)
|
2019-04-25 |
2025-12-16 |
Avidity Biosciences, Inc. |
Nucleic acid compositions and methods of multi-exon skipping
|
|
US11535634B2
(en)
|
2019-06-05 |
2022-12-27 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
|
JP7592034B2
(ja)
|
2019-06-06 |
2024-11-29 |
アビディティー バイオサイエンシーズ，インク． |
核酸ポリペプチド組成物およびその使用
|
|
KR20220019259A
(ko)
|
2019-06-06 |
2022-02-16 |
어비디티 바이오사이언시스 인크. |
Una 아미다이트 및 이의 용도
|
|
KR20220061977A
(ko)
|
2019-08-12 |
2022-05-13 |
퓨리노미아 바이오테크, 아이엔씨. |
Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물
|
|
WO2021064184A1
(en)
|
2019-10-04 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
|
TW202131954A
(zh)
|
2019-11-07 |
2021-09-01 |
丹麥商珍美寶股份有限公司 |
利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
|
|
MX2022005222A
(es)
|
2019-11-07 |
2022-06-08 |
Genmab As |
Metodos para tratar el cancer con una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y un conjugado de anticuerpo anti factor tisular-farmaco.
|
|
EP4684799A2
(en)
|
2019-12-06 |
2026-01-28 |
TrueBinding, Inc. |
Antibodies that disrupt the interaction of gal3 and insulin receptor or integrins and methods of use thereof
|
|
US11555190B2
(en)
|
2020-03-19 |
2023-01-17 |
Avidity Biosciences, Inc. |
Compositions and methods of treating Facioscapulohumeral muscular dystrophy
|
|
AU2021241682B2
(en)
|
2020-03-27 |
2026-02-12 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle dystrophy
|
|
WO2021193928A1
(ja)
*
|
2020-03-27 |
2021-09-30 |
株式会社ＰｈｏｔｏＱ３ |
腫瘍細胞を死滅させるための医薬
|
|
CA3182333A1
(en)
|
2020-05-20 |
2021-11-25 |
Institut Curie |
Single domain antibodies and their use in cancer therapies
|
|
WO2021242776A2
(en)
|
2020-05-26 |
2021-12-02 |
Truebinding, Inc. |
Methods of treating inflammatory diseases by blocking galectin-3
|
|
MX2022015375A
(es)
|
2020-06-29 |
2023-01-16 |
Genmab As |
Conjugados de farmaco-anticuerpo anti-factor de tejido y su uso en el tratamiento de cancer.
|
|
WO2022029080A1
(en)
|
2020-08-03 |
2022-02-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
|
CN112062855B
(zh)
|
2020-08-26 |
2024-08-30 |
北京天诺健成医药科技有限公司 |
一种含有衔接器的药物治疗剂的开发和应用
|
|
WO2022079270A1
(en)
|
2020-10-16 |
2022-04-21 |
Université D'aix-Marseille |
Anti-gpc4 single domain antibodies
|
|
CN114524878B
(zh)
|
2020-11-23 |
2024-08-02 |
康诺亚生物医药科技（成都）有限公司 |
一种双特异性抗体及其用途
|
|
CN114573702A
(zh)
|
2020-12-02 |
2022-06-03 |
康诺亚生物医药科技（成都）有限公司 |
一种新型肿瘤衔接器治疗药物的开发和应用
|
|
CN114573703A
(zh)
|
2020-12-02 |
2022-06-03 |
康诺亚生物医药科技（成都）有限公司 |
一种t细胞衔接器治疗剂的开发和应用
|
|
CN114685657B
(zh)
|
2020-12-31 |
2024-08-16 |
康诺亚生物医药科技（成都）有限公司 |
一种功能增强型抗体阻断剂的开发及其应用
|
|
JP2024505428A
(ja)
|
2021-01-14 |
2024-02-06 |
アンスティテュ キュリー |
Ｈｅｒ２単一ドメイン抗体バリアントおよびそのｃａｒ
|
|
WO2022182415A1
(en)
|
2021-02-24 |
2022-09-01 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
|
KR20240012352A
(ko)
|
2021-03-23 |
2024-01-29 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
T 세포 림프종의 진단 및 치료 방법
|
|
EP4320153A1
(en)
|
2021-04-09 |
2024-02-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
|
JP2024526764A
(ja)
|
2021-07-13 |
2024-07-19 |
トゥルーバインディング，インコーポレイテッド |
タンパク質凝集を防止する方法
|
|
MX2024002571A
(es)
|
2021-09-03 |
2024-03-20 |
Toray Industries |
Composicion farmaceutica para tratamiento y/o prevencion de cancer.
|
|
MX2024003266A
(es)
|
2021-09-16 |
2024-04-03 |
Avidity Biosciences Inc |
Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
|
|
WO2023041717A1
(en)
|
2021-09-16 |
2023-03-23 |
Aboleris Pharma |
Anti-human cd45rc binding domains and uses thereof
|
|
CA3238590A1
(en)
|
2021-11-09 |
2023-05-19 |
Truebinding, Inc. |
Methods of treating or inhibiting cardiovascular diseases
|
|
EP4448095A1
(en)
|
2021-12-14 |
2024-10-23 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
|
AU2022422149A1
(en)
|
2021-12-23 |
2024-08-01 |
Mirecule, Inc. |
Compositions for delivery of polynucleotides
|
|
US20250067745A1
(en)
|
2022-01-31 |
2025-02-27 |
Institut National de la Santé et de la Recherche Médicale |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
|
KR20230144960A
(ko)
|
2022-04-07 |
2023-10-17 |
트윈피그바이오랩(주) |
신규 펩타이드 기반 면역항암제
|
|
JP2025514669A
(ja)
|
2022-04-11 |
2025-05-09 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Ｔ細胞悪性腫瘍の診断及び処置のための方法
|
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
|
JP2025515486A
(ja)
|
2022-04-29 |
2025-05-15 |
ピュリノミア バイオテック， インコーポレイテッド |
好酸球駆動性疾患及び障害を治療するための方法及び組成物
|
|
WO2023213960A1
(en)
|
2022-05-06 |
2023-11-09 |
Genmab A/S |
Methods of treating cancer with anti-tissue factor antibody-drug conjugates
|
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
|
JP2025526336A
(ja)
|
2022-07-22 |
2025-08-13 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Ｔ細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのｇａｒｐ
|
|
IL318625A
(en)
|
2022-07-29 |
2025-03-01 |
Regeneron Pharma |
Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle
|
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
|
EP4602372A1
(en)
|
2022-10-12 |
2025-08-20 |
Institut National de la Santé et de la Recherche Médicale |
Cd81 as a biomarker and biotarget in t-cell malignancies
|
|
AU2023379457A1
(en)
|
2022-11-14 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
JP2026506554A
(ja)
|
2023-02-06 |
2026-02-25 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
多重塩基編集による遺伝子改変造血幹細胞の濃縮
|
|
WO2024170543A1
(en)
|
2023-02-14 |
2024-08-22 |
Institut National de la Santé et de la Recherche Médicale |
Anti-cd44 antibodies and uses thereof
|
|
CN121285385A
(zh)
|
2023-05-12 |
2026-01-06 |
金麦安博股份有限公司 |
能够与ox40结合的抗体、其变体及其用途
|
|
CN121794380A
(zh)
|
2023-06-27 |
2026-04-03 |
艾维迪提生物科学公司 |
使用prkag2靶向性抗体-寡核苷酸缀合物的组合物和方法
|
|
WO2025007063A1
(en)
|
2023-06-30 |
2025-01-02 |
Avidity Biosciences, Inc. |
Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates
|
|
WO2025120015A1
(en)
|
2023-12-06 |
2025-06-12 |
Institut National de la Santé et de la Recherche Médicale |
Cd5 targeting antibodies with depleting and t or b-cell activation effects
|
|
EP4624494A1
(en)
|
2024-03-29 |
2025-10-01 |
Institut Curie |
Her2 single domain antibody and uses thereof
|
|
WO2025238052A1
(en)
|
2024-05-15 |
2025-11-20 |
Institut National de la Santé et de la Recherche Médicale |
Depletion of plasmacytoid dendritic cells for the treatment of respiratory viral infections
|
|
WO2026077659A1
(en)
|
2024-09-17 |
2026-04-16 |
Institut National de la Santé et de la Recherche Médicale |
Enrichment of genetically modified hematopoietic stem cells through epigenome editing
|
|
WO2026061986A1
(en)
|
2024-09-17 |
2026-03-26 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotide (aso)-mediated down-regulation of cd33 to safely enrich for genetically modified cells
|